OvaScience Company Profile (NASDAQ:OVAS)

About OvaScience (NASDAQ:OVAS)

OvaScience logoOvaScience, Inc. is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company's portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient's own ovarian tissue. The Company's AUGMENT treatment is designed to improve egg health by supplementing a mitochondrial deficiency. With the AUGMENT treatment, energy-producing mitochondria from a patient's own EggPC cells are added to the patient's mature eggs during the in vitro fertilization process to supplement the existing mitochondria. Its OvaPrime treatment is a fertility treatment designed to replenish a woman's ovary by increasing her egg reserve using her own EggPC cells. Its OvaTure treatment is a fertility treatment that seeks to create mature fertilizable eggs in vitro from a woman's own EggPC cells without the need for hormone hyperstimulation.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: N/A
  • Symbol: NASDAQ:OVAS
  • CUSIP: N/A
  • Web: www.ovascience.com
  • Market Cap: $52.42 million
  • Outstanding Shares: 35,662,000
Average Prices:
  • 50 Day Moving Avg: $1.47
  • 200 Day Moving Avg: $1.52
  • 52 Week Range: $1.25 - $8.98
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.00
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $569,999.00
  • Price / Sales: 96.98
  • Book Value: $2.66 per share
  • Price / Book: 0.58
  • EBIDTA: ($64,780,000.00)
  • Net Margins: -13,227.72%
  • Return on Equity: -61.67%
  • Return on Assets: -55.78%
  • Current Ratio: 9.55%
  • Quick Ratio: 9.55%
  • Average Volume: 454,190 shs.
  • Beta: 3.52
  • Short Ratio: 18.47

Frequently Asked Questions for OvaScience (NASDAQ:OVAS)

What is OvaScience's stock symbol?

OvaScience trades on the NASDAQ under the ticker symbol "OVAS."

How were OvaScience's earnings last quarter?

OvaScience Inc. (NASDAQ:OVAS) announced its earnings results on Tuesday, May, 9th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.46) by $0.08. The firm earned $0.06 million during the quarter, compared to analyst estimates of $0.12 million. OvaScience had a negative return on equity of 61.67% and a negative net margin of 13,227.72%. The business's revenue was down 56.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.80) EPS. View OvaScience's Earnings History.

Where is OvaScience's stock going? Where will OvaScience's stock price be in 2017?

5 brokers have issued 1-year price objectives for OvaScience's shares. Their predictions range from $1.00 to $15.00. On average, they anticipate OvaScience's stock price to reach $8.00 in the next year. View Analyst Ratings for OvaScience.

Who are some of OvaScience's key competitors?

Who are OvaScience's key executives?

OvaScience's management team includes the folowing people:

  • Michelle Dipp M.D., Ph.D., Executive Chairman of the Board, Acting President, Chief Executive Officer, Principal Executive Officer
  • Chris A. Kroeger M.D., Chief Executive Officer
  • Jonathan Gillis, principal Financial Officer, principal Accounting Officer, Vice President
  • Karen Long, Executive Vice President - Clinical and Regulatory Affairs and Quality Assurance
  • James Luterman Ph.D., Executive Vice President - Research and Development
  • Theresa McNeely, Executive Vice President, Chief Communications Officer
  • Ravi Mehrotra Ph.D., Chief Corporate Development Officer
  • Richard H. Aldrich, Lead Independent Director
  • John P. Howe III M.D., Director
  • John E. Sexton Ph.D., Director

How do I buy OvaScience stock?

Shares of OvaScience can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is OvaScience's stock price today?

One share of OvaScience stock can currently be purchased for approximately $1.55.

MarketBeat Community Rating for OvaScience (NASDAQ OVAS)
Community Ranking:  2.9 out of 5 ( )
Outperform Votes:  135 (Vote Outperform)
Underperform Votes:  101 (Vote Underperform)
Total Votes:  236
MarketBeat's community ratings are surveys of what our community members think about OvaScience and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for OvaScience (NASDAQ:OVAS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 3 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $8.00 (416.13% upside)

Analysts' Ratings History for OvaScience (NASDAQ:OVAS)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/22/2017Oppenheimer Holdings, Inc.Reiterated RatingHoldHighView Rating Details
5/12/2017HC WainwrightReiterated RatingBuy$15.00LowView Rating Details
4/18/2017Credit Suisse GroupReiterated RatingUnderperform -> Underperform$1.00LowView Rating Details
8/10/2016JMP SecuritiesReiterated RatingNeutralN/AView Rating Details
8/5/2016J P Morgan Chase & CoLower Price TargetNeutral$9.00 -> $8.00N/AView Rating Details
5/8/2016Leerink SwannReiterated RatingHold$6.00 -> $7.00N/AView Rating Details
3/21/2016S&P Equity ResearchLower Price Target$10.82 -> $8.83N/AView Rating Details
10/2/2015WedbushLower Price TargetOutperform$46.00 -> $15.00N/AView Rating Details
(Data available from 7/21/2015 forward)


Earnings History for OvaScience (NASDAQ:OVAS)
Earnings by Quarter for OvaScience (NASDAQ:OVAS)
Earnings History by Quarter for OvaScience (NASDAQ OVAS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017($0.46)($0.38)$0.12 million$0.06 millionViewListenView Earnings Details
3/2/2017Q4 2016($0.58)($0.64)$0.11 million$0.12 millionViewListenView Earnings Details
11/3/2016Q316($0.62)($0.54)$0.25 million$0.02 millionViewListenView Earnings Details
8/4/2016Q216($0.78)($0.62)$0.21 million$0.19 millionViewListenView Earnings Details
5/5/2016Q116($0.72)($0.80)$0.14 million$0.15 millionViewListenView Earnings Details
2/25/2016Q315($0.71)($0.76)$0.20 million$0.16 millionViewListenView Earnings Details
11/5/2015Q3($0.68)($0.66)$0.17 million$0.08 millionViewN/AView Earnings Details
8/10/2015Q215($0.64)($0.64)$0.57 million$0.03 millionViewN/AView Earnings Details
5/11/2015($0.65)($0.65)$0.40 million$0.02 millionViewN/AView Earnings Details
3/16/2015Q414($0.59)($0.79)ViewN/AView Earnings Details
11/10/2014Q314($0.44)($0.54)ViewN/AView Earnings Details
8/7/2014Q214($0.45)($0.42)ViewN/AView Earnings Details
5/8/2014($0.46)($0.41)ViewN/AView Earnings Details
2/27/2014Q413($0.39)($0.64)ViewN/AView Earnings Details
11/13/2013Q313($0.35)($0.40)ViewN/AView Earnings Details
8/13/2013Q213($0.28)($0.36)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for OvaScience (NASDAQ:OVAS)
2017 EPS Consensus Estimate: ($1.49)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.35)($0.35)($0.35)
Q2 20171($0.41)($0.41)($0.41)
Q3 20171($0.41)($0.41)($0.41)
Q4 20171($0.32)($0.32)($0.32)
(Data provided by Zacks Investment Research)


Dividend History for OvaScience (NASDAQ:OVAS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for OvaScience (NASDAQ:OVAS)
Insider Ownership Percentage: 12.59%
Institutional Ownership Percentage: 63.66%
Insider Trades by Quarter for OvaScience (NASDAQ:OVAS)
Institutional Ownership by Quarter for OvaScience (NASDAQ:OVAS)
Insider Trades by Quarter for OvaScience (NASDAQ:OVAS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/1/2016Michelle DippCEOBuy425,000$7.00$2,975,000.00View SEC Filing  
5/18/2016Michelle DippCEOBuy20,000$7.86$157,200.00View SEC Filing  
5/17/2016Michelle DippCEOBuy40,000$7.63$305,200.00View SEC Filing  
5/13/2016Richard AldrichDirectorBuy36,095$6.94$250,499.30View SEC Filing  
5/11/2016Richard AldrichDirectorBuy20,000$7.64$152,800.00View SEC Filing  
5/10/2016Michelle DippCEOBuy19,900$7.72$153,628.00View SEC Filing  
5/10/2016Paul W.D. ChapmanCOOBuy3,100$7.37$22,847.00View SEC Filing  
3/24/2016Michelle DippCEOBuy59,800$9.49$567,502.00View SEC Filing  
3/22/2016Michelle DippCEOBuy59,800$10.44$624,312.00View SEC Filing  
3/18/2016Michelle DippCEOBuy59,700$8.26$493,122.00View SEC Filing  
3/16/2016Michelle DippCEOBuy59,029$7.90$466,329.10View SEC Filing  
3/14/2016Michelle DippCEOBuy162,732$7.60$1,236,763.20View SEC Filing  
10/5/2015Jeffrey E YoungCFOBuy3,450$10.70$36,915.00View SEC Filing  
10/5/2015Marc D KozinDirectorBuy4,800$10.79$51,792.00View SEC Filing  
9/9/2015Mary FisherDirectorBuy6,100$16.49$100,589.00View SEC Filing  
9/8/2015Marc D KozinDirectorBuy3,000$17.60$52,800.00View SEC Filing  
4/8/2015Marc D KozinDirectorBuy3,000$28.45$85,350.00View SEC Filing  
4/2/2015Michelle DippCEOBuy1,000$32.49$32,490.00View SEC Filing  
1/13/2015Thomas MalleyDirectorBuy35,000$50.00$1,750,000.00View SEC Filing  
7/7/2014Richard AldrichDirectorBuy2,000$9.49$18,980.00View SEC Filing  
6/30/2014Richard AldrichDirectorBuy2,000$9.16$18,320.00View SEC Filing  
6/23/2014Richard AldrichDirectorBuy2,000$8.81$17,620.00View SEC Filing  
6/16/2014Richard AldrichDirectorBuy2,000$8.52$17,040.00View SEC Filing  
6/9/2014Richard AldrichDirectorBuy2,000$7.59$15,180.00View SEC Filing  
6/3/2014Harald F StockDirectorBuy1,063$7.01$7,451.63View SEC Filing  
6/2/2014Richard AldrichDirectorBuy2,000$7.29$14,580.00View SEC Filing  
5/27/2014Richard AldrichDirectorBuy2,000$7.50$15,000.00View SEC Filing  
5/20/2014Harald F StockDirectorBuy1,050$7.13$7,486.50View SEC Filing  
5/19/2014Richard AldrichDirectorBuy2,000$7.33$14,660.00View SEC Filing  
3/7/2014Fund L.P. LongwoodMajor ShareholderBuy100,000$10.00$1,000,000.00View SEC Filing  
9/12/2013Arthur TzianabosInsiderBuy1,000$10.32$10,320.00View SEC Filing  
9/12/2013Harald F StockDirectorBuy4,500$10.64$47,880.00View SEC Filing  
9/11/2013Christopher A BleckInsiderBuy2,000$11.15$22,300.00View SEC Filing  
9/11/2013Richard AldrichDirectorBuy4,850$10.54$51,119.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for OvaScience (NASDAQ:OVAS)
Latest Headlines for OvaScience (NASDAQ:OVAS)
americanbankingnews.com logoOvaScience Inc. (OVAS) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - July 10 at 9:55 AM
americanbankingnews.com logoOppenheimer Holdings Brokers Cut Earnings Estimates for OvaScience Inc. (OVAS)
www.americanbankingnews.com - June 26 at 7:10 AM
streetinsider.com logoForm 4 OvaScience, Inc. For: Jun 21 Filed by: ALDRICH RICHARD - StreetInsider.com
www.streetinsider.com - June 24 at 7:37 PM
streetinsider.com logoForm 3 OvaScience, Inc. For: Jun 21 Filed by: GILLIS JONATHAN - StreetInsider.com
www.streetinsider.com - June 24 at 7:37 PM
americanbankingnews.com logoOvaScience Inc. (OVAS) Receives Hold Rating from Oppenheimer Holdings, Inc.
www.americanbankingnews.com - June 24 at 11:56 AM
streetinsider.com logoForm 4 OvaScience, Inc. For: Jun 21 Filed by: CAPELLO JEFFREY D - StreetInsider.com
www.streetinsider.com - June 24 at 12:48 AM
News IconBRIEF-OvaScience appoints Christopher Kroeger as CEO
www.businessinsider.com - June 23 at 8:51 AM
finance.yahoo.com logoETFs with exposure to OvaScience, Inc. : June 22, 2017
finance.yahoo.com - June 23 at 8:51 AM
businesswire.com logoOvaScience Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - Business Wire (press release)
www.businesswire.com - June 22 at 7:14 AM
finance.yahoo.com logoOvaScience Appoints Christopher Kroeger, M.D., M.B.A., as Chief Executive Officer
finance.yahoo.com - June 22 at 7:14 AM
finance.yahoo.com logoWaltham’s OvaScience names new CEO, cuts half its staff
finance.yahoo.com - June 22 at 7:14 AM
finance.yahoo.com logoOvaScience Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
finance.yahoo.com - June 22 at 7:14 AM
streetinsider.com logoOvaScience (OVAS) Completes Enrollment in OvaPrime Clinical Study in Women with POI or POR
www.streetinsider.com - June 13 at 7:12 PM
americanbankingnews.com logoOvaScience Inc. (OVAS) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - June 13 at 11:14 AM
seekingalpha.com logoOvaScience completes enrollment in OvaPrime study - Seeking Alpha
seekingalpha.com - June 13 at 10:34 AM
finance.yahoo.com logoOvaScience Completes Enrollment of 70 Patients in OvaPrime Clinical Study in Women with Primary Ovarian Insufficiency or Poor Ovarian Response
finance.yahoo.com - June 13 at 10:34 AM
finance.yahoo.com logoETFs with exposure to OvaScience, Inc. : June 5, 2017
finance.yahoo.com - June 5 at 7:42 PM
americanbankingnews.com logoOvaScience Inc (OVAS) Expected to Announce Quarterly Sales of $90,000.00
www.americanbankingnews.com - June 4 at 8:40 AM
finance.yahoo.com logoOvaScience, Inc. :OVAS-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017
finance.yahoo.com - June 2 at 9:21 PM
americanbankingnews.com logo Analysts Anticipate OvaScience Inc (OVAS) to Post -$0.44 Earnings Per Share
www.americanbankingnews.com - June 2 at 2:34 PM
finance.yahoo.com logoIMPORTANT EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against OvaScience, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - May 23 at 6:35 PM
americanbankingnews.com logoOvaScience Inc (OVAS) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - May 19 at 1:42 PM
americanbankingnews.com logoZacks Investment Research Lowers OvaScience Inc (OVAS) to Sell
www.americanbankingnews.com - May 13 at 7:52 AM
americanbankingnews.com logoOvaScience's (OVAS) "Buy" Rating Reaffirmed at HC Wainwright
www.americanbankingnews.com - May 12 at 5:20 PM
americanbankingnews.com logoQ2 2017 EPS Estimates for OvaScience Inc Cut by Oppenheimer Holdings (OVAS)
www.americanbankingnews.com - May 12 at 8:50 AM
seekingalpha.com logoOvaScience beats by $0.01, misses on revenue
seekingalpha.com - May 12 at 12:34 AM
americanbankingnews.com logoOvaScience Inc (OVAS) Expected to Post Quarterly Sales of $130,000.00
www.americanbankingnews.com - May 11 at 12:20 PM
americanbankingnews.com logoOvaScience Inc (OVAS) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 10 at 7:40 PM
finance.yahoo.com logoEdited Transcript of OVAS earnings conference call or presentation 9-May-17 8:30pm GMT
finance.yahoo.com - May 10 at 11:47 AM
finance.yahoo.com logoOvaScience Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 9 at 6:41 PM
finance.yahoo.com logoOvaScience reports 1Q loss
finance.yahoo.com - May 9 at 6:41 PM
americanbankingnews.com logo-$0.46 Earnings Per Share Expected for OvaScience Inc (OVAS) This Quarter
www.americanbankingnews.com - May 9 at 7:46 AM
americanbankingnews.com logoOvaScience Inc (OVAS) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - May 7 at 6:26 PM
finance.yahoo.com logoINVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against OvaScience, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - May 5 at 7:22 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against OvaScience, Inc. (OVAS) and Lead Plaintiff Deadline - May 29, 2017
finance.yahoo.com - May 4 at 7:16 PM
americanbankingnews.com logoSomewhat Favorable Media Coverage Extremely Likely to Impact OvaScience (OVAS) Share Price
www.americanbankingnews.com - May 4 at 2:34 PM
businesswire.com logoOvaScience to Host First Quarter 2017 Financial Results Conference Call
www.businesswire.com - May 3 at 7:57 PM
finance.yahoo.com logoDEADLINE ALERT: Brower Piven Alerts Shareholders of Approaching Deadline in Class Action Lawsuit and Encourages Those with Losses in Excess of $100,000 from Investment in OvaScience, Inc. to Contact the Firm
finance.yahoo.com - May 2 at 4:52 PM
finance.yahoo.com logoIMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against OvaScience, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - May 2 at 4:52 PM
americanbankingnews.com logoOvaScience (OVAS) Receives Daily Media Impact Score of 0.26
www.americanbankingnews.com - May 1 at 3:32 PM
americanbankingnews.com logoOvaScience (OVAS) Earns News Impact Score of 0.17
www.americanbankingnews.com - April 28 at 4:45 PM
americanbankingnews.com logoOvaScience Inc (OVAS) Short Interest Up 29.7% in April
www.americanbankingnews.com - April 27 at 7:16 AM
americanbankingnews.com logoOvaScience (OVAS) Getting Somewhat Positive Media Coverage, Analysis Shows
www.americanbankingnews.com - April 25 at 6:46 PM
prnewswire.com logoSHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In OvaScience, Inc. To ... - PR Newswire (press release)
www.prnewswire.com - April 21 at 9:05 AM
americanbankingnews.com logoOvaScience Inc (OVAS) Expected to Post Quarterly Sales of $120,000.00
www.americanbankingnews.com - April 20 at 1:53 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Goldberg Law PC Announces the Filing of a Securities Class Action Lawsuit Against OvaScience, Inc.
finance.yahoo.com - April 19 at 7:07 PM
americanbankingnews.com logoCredit Suisse Group AG Begins Coverage on OvaScience Inc (OVAS)
www.americanbankingnews.com - April 18 at 11:50 AM
americanbankingnews.com logoOvaScience Inc (OVAS) Expected to Announce Earnings of -$0.46 Per Share
www.americanbankingnews.com - April 18 at 11:38 AM
americanbankingnews.com logoOvaScience (OVAS) Earns Coverage Optimism Score of 0.16
www.americanbankingnews.com - April 17 at 11:03 PM
americanbankingnews.com logoOvaScience (OVAS) Earning Positive Media Coverage, Report Finds
www.americanbankingnews.com - April 13 at 5:27 PM



OvaScience (OVAS) Chart for Friday, July, 21, 2017

This page was last updated on 7/21/2017 by MarketBeat.com Staff